Most Read Articles
6 days ago
Intra-articular injections of botulinum toxin-A deliver substantial short-term benefits in terms of pain reduction in patients with refractory joint pain, according to a meta-analysis.
16 Aug 2017
At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.
Roshini Claire Anthony, 15 Jul 2017

Adding midostaurin to standard chemotherapy appeared to improve overall survival (OS) in patients recently diagnosed with acute myeloid leukaemia (AML) with a FLT3 mutation, according to a recent study.

Pearl Toh, 10 May 2017
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.

Omalizumab safe, well-tolerated in Asian patients with urticaria

10 Apr 2017

Omalizumab appears to effectively reduce the signs and symptoms of chronic spontaneous urticaria (CSU) in Japanese and Korean patients who remain symptomatic despite the use of nonsedating second-generation H1 antihistamines (H1AH), according to the results of POLARIS study.

The phase III trial randomized 218 H1AH-refractory CSU patients to treatment with omalizumab 300 mg (n=73; mean age 44.6 years; 54.8 percent female), 150 mg (n=71; mean age 43.6 years; 60.6 percent female) or placebo (n=74; mean age 42.5 years; 64.9 percent female). Treatment was administered three times, given subcutaneously every 4 weeks (days 1, 29 and 57), followed by 12 weeks of follow-up.

The primary outcome measure was change from baseline to week 12 in weekly itch severity score (ISS7). Safety was assessed through the summary of adverse events (AEs).

At week 12, reductions from baseline in ISS7 were significantly higher with omalizumab vs placebo (mean changes, −10.22 for 300 mg and −8.80 for 150 mg vs −6.51; p<0.001 and p=0.006 vs placebo, respectively).

Overall AE incidence did not significantly differ across treatment groups (54.8, 57.7 and 55.4 percent in omalizumab 300 mg, 150 mg and placebo arms, respectively), with nasopharyngitis as the most frequently reported AE.

CSU is a skin disorder characterized by the spontaneous development of hives, angioedema or both, that last for 6 weeks or more. Treatment with H1AH is the current standard of care, and current guidelines recommend dose intensification (up to fourfold) if symptoms persist after 2 weeks. Despite this approach, however, there are still some patients who do not respond or have insufficient response to H1AH. [Allergy 2014; 69: 868–887; Allergy Asthma Immunol Res 2012;4:326–331]

The findings indicate that omalizumab is a well-tolerated treatment option in Japanese and Korean patients who remain symptomatic despite the use of H1AH.

Moreover, the study provides evidence “that ethnic differences do not affect treatment outcomes in patients with CSU who are treated with omalizumab, [a recombinant humanized monoclonal antibody that inhibits IgE-mediated cellular responses]; this is consistent with studies of omalizumab for the treatment of asthma,” researchers said. [Allergol Int 2015;64:364–370; Respirology 2009;14:1156–1165; Allergol Int 2010;59:167–174; Drug Metab Pharmacokinet 2016;31:173–184]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
6 days ago
Intra-articular injections of botulinum toxin-A deliver substantial short-term benefits in terms of pain reduction in patients with refractory joint pain, according to a meta-analysis.
16 Aug 2017
At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.
Roshini Claire Anthony, 15 Jul 2017

Adding midostaurin to standard chemotherapy appeared to improve overall survival (OS) in patients recently diagnosed with acute myeloid leukaemia (AML) with a FLT3 mutation, according to a recent study.

Pearl Toh, 10 May 2017
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.